CO6160230A2 - Arilsulfonamidas con efecto analgesico - Google Patents

Arilsulfonamidas con efecto analgesico

Info

Publication number
CO6160230A2
CO6160230A2 CO09016433A CO09016433A CO6160230A2 CO 6160230 A2 CO6160230 A2 CO 6160230A2 CO 09016433 A CO09016433 A CO 09016433A CO 09016433 A CO09016433 A CO 09016433A CO 6160230 A2 CO6160230 A2 CO 6160230A2
Authority
CO
Colombia
Prior art keywords
group
twice
substituted
substituted once
alkyl
Prior art date
Application number
CO09016433A
Other languages
English (en)
Inventor
Hefner Iris Kauffmann
Norbert Hauel
Rainer Walter
Heiner Ebel
Henri Doods
Angelo Ceci
Annette Schuler-Metz
Ingo Konetzki
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO6160230A2 publication Critical patent/CO6160230A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/04Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)

Abstract

1.- Compuestos de la fórmula general len la que A significa un enlace o -alquileno C1-4 o -CH2-C(O)-, B significa un enlace, -alquileno C1-3, -O- o -C(O)-, D significa un grupo de las fórmulas generales IIY significa un grupo -alquileno C1-6, eventualmente sustituido con el radical R2, en donde un grupo metileno puede estar reemplazado adicionalmente por Y1 e Y1 representa -O-, -S-, -S(O)-, -N(R2)-, -N(R2)-C(O)-, C(O)N(R2), -C(O)-, -CH(arilo)-, cicloalquileno C3-6 o -S(O)2-, R1 significa cicloalquilo C3-7- o arilo-, heteroarilo- o aril-alquilo C1-3-, que en cada caso pueden estar sustituidos con uno, dos, tres o cuatro radicales R1.1, en donde los radicales R1.1 pueden ser iguales o diferentes, yR1.1 representa H, F, CI, Br, I, alquilo C1-3-, F3C-, HO-, alquil C1-3-O- o alquil C1-3-O-alquilen C2-4-O-,R2 significa H o alquilo C1-3, en donde cada grupo metileno puede estar sustituido con hasta dos y cada grupo metilo puede estar sustituido con hasta tres átomos de fluoro, o también H3C-C(O)-, R3 significa a) -alquileno C1-6, b) un grupo cicloalquileno C3-6, sustituido una vez, dos o tres veces con R3.1, c) un grupo cicloalquenileno C3-6, sustituido una vez o dos veces con R3.1, que está condensado con un anillo de fenilo a través del enlace insaturado, d) -N(R3)-, e) un grupo arileno sustituido una vez o dos veces con R3.1, f) un grupo heteroarileno sustituido una vez o dos veces con R3.1, g) un anillo heterocíclico de 4 a 7 miembros, saturado, sustituido una o dos veces con R3.1, h) un anillo heterociclico de 5 a 7 miembros, insaturado, sustituido una o dos veces con R3.1, que está condensado a través de los enlaces insaturados con uno o dos anillos de fenilo o i) un aza-heterobiciclo de 8 a 10 miembros, saturado, ...
CO09016433A 2006-08-19 2009-02-19 Arilsulfonamidas con efecto analgesico CO6160230A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006039003A DE102006039003A1 (de) 2006-08-19 2006-08-19 Neue Verbindungen

Publications (1)

Publication Number Publication Date
CO6160230A2 true CO6160230A2 (es) 2010-05-20

Family

ID=38925625

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09016433A CO6160230A2 (es) 2006-08-19 2009-02-19 Arilsulfonamidas con efecto analgesico

Country Status (20)

Country Link
US (2) US7858618B2 (es)
EP (3) EP2402329B1 (es)
JP (3) JP5291623B2 (es)
KR (1) KR20090047535A (es)
CN (1) CN101516867A (es)
AR (1) AR062426A1 (es)
AU (1) AU2007287652A1 (es)
BR (1) BRPI0715645A2 (es)
CA (1) CA2663598A1 (es)
CL (1) CL2007002407A1 (es)
CO (1) CO6160230A2 (es)
DE (1) DE102006039003A1 (es)
EA (1) EA200900279A1 (es)
IL (1) IL197021A0 (es)
MX (1) MX2009001791A (es)
NO (2) NO20090079L (es)
SG (3) SG169339A1 (es)
TW (1) TW200815394A (es)
WO (1) WO2008022945A1 (es)
ZA (1) ZA200810782B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006039003A1 (de) 2006-08-19 2008-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Verbindungen
DE102007034620A1 (de) * 2007-07-25 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue B1-Antagonisten
EP2025675A1 (de) * 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamide mit analgetischer Wirkung
US20110046106A1 (en) * 2008-02-06 2011-02-24 Boehringer Ingelheim International Gmbh Aryl sulfonamides as effective analgesics
RU2503674C2 (ru) * 2008-04-08 2014-01-10 Грюненталь Гмбх Замещенные производные сульфонамида
JP2011525183A (ja) 2008-06-20 2011-09-15 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なイミダゾピリジンおよびイミダゾピラジン化合物
AU2009272486A1 (en) * 2008-07-18 2010-01-21 Takeda Pharmaceutical Company Limited. Benzazepine derivatives and their use as hstamine H3 antagonists
BRPI0914556A2 (pt) * 2008-08-12 2015-08-04 Boehringer Ingelheim Int Processo para a preparação de compostos de piperazina substituídos por cicloalquila
US8207335B2 (en) * 2009-02-13 2012-06-26 Boehringer Ingelheim International Gmbh Process for making certain compounds having B1 antagonistic activity
EP2616073A4 (en) * 2010-09-13 2015-02-18 Microbiotix Inc INHIBITORS OF IMMERSION OF VIRUSES IN MAMMALIAN HOST CELLS
WO2014009319A1 (en) 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Indolinone derivatives anticancer compounds
KR101735705B1 (ko) 2015-09-22 2017-05-15 주식회사 에코시안 건물 에너지 효율화 평가 방법 및 장치
CN105153168A (zh) * 2015-09-29 2015-12-16 上海天慈国际药业有限公司 N-[4-(2-甲基-4,5-二氢-3H-咪唑并[4,5-d][1]苯并氮杂卓-6-甲酰基)苯基]-2-苯基苯甲酰胺盐酸盐的制备方法
KR101645157B1 (ko) 2015-11-10 2016-08-02 주식회사 넥스미디어 통합 음식 제공 서비스 방법 및 장치
WO2019058393A1 (en) 2017-09-22 2019-03-28 Jubilant Biosys Limited HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PAD
SG11202003463XA (en) 2017-10-18 2020-05-28 Jubilant Epipad LLC Imidazo-pyridine compounds as pad inhibitors
CN111386265A (zh) 2017-11-06 2020-07-07 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1活化的抑制剂的嘧啶衍生物
MX2020005363A (es) 2017-11-24 2020-10-01 Jubilant Episcribe Llc Compuestos heterociclicos como inhibidores de prmt5.
EP3765453A1 (en) 2018-03-13 2021-01-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1100635B (de) 1958-04-22 1961-03-02 Rhone Poulenc Sa Verfahren zur Herstellung von Phenthiazinderivaten
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
IL115420A0 (en) * 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
EP1249233B9 (en) 1999-11-26 2009-08-05 Shionogi & Co., Ltd. Npyy5 antagonists
FR2819254B1 (fr) * 2001-01-08 2003-04-18 Fournier Lab Sa Nouveaux composes de la n-(phenylsulfonyl) glycine, leur procede de preparation et leur utilisation pour obtenir des compostions pharmaceutiques
FR2840897B1 (fr) * 2002-06-14 2004-09-10 Fournier Lab Sa Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
EP1572678A4 (en) 2002-12-19 2008-05-07 Elan Pharm Inc SUBSTITUTED N-PHENYL SULPHONAMIDES ALSBRADYKININ ANTAGONISTS
BRPI0408689B8 (pt) * 2003-03-25 2021-05-25 Laboratoires Fournier S A derivados de benzenosulfonamida, método para preparação e utilização disso para o tratamento da dor
CA2553676A1 (en) * 2004-01-28 2005-08-11 Research Development Foundation Human soluble neuropilin-1 primary polyadenylation signal and uses thereof
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
EP1799637A1 (en) * 2004-09-23 2007-06-27 Amgen, Inc Substituted sulfonamidopropionamides and methods of use
US20080090863A1 (en) 2004-09-30 2008-04-17 Taisho Pharmaceutical Co., Ltd. Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor
DE102005013967A1 (de) * 2004-11-05 2006-10-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2006071775A2 (en) 2004-12-29 2006-07-06 Elan Pharmaceuticals, Inc. Novel compounds useful for bradykinin b1 receptor antagonism
DE102006039003A1 (de) 2006-08-19 2008-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Verbindungen
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
DE102007034620A1 (de) * 2007-07-25 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue B1-Antagonisten
US8394805B2 (en) 2007-08-14 2013-03-12 Boehringer Ingelheim International Gmbh Compounds
EP2212281B1 (de) * 2007-08-14 2011-03-23 Boehringer Ingelheim International GmbH Arylsulfonamide mit analgetischer wirkung
DE102007046887A1 (de) * 2007-09-28 2009-04-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von (1R,5S)-Anhydroecgoninestersalzen

Also Published As

Publication number Publication date
JP2013177392A (ja) 2013-09-09
MX2009001791A (es) 2009-03-02
EP2402329B1 (de) 2013-05-22
BRPI0715645A2 (pt) 2013-07-09
EP2402329A1 (de) 2012-01-04
US20110021488A1 (en) 2011-01-27
US7858618B2 (en) 2010-12-28
JP5291623B2 (ja) 2013-09-18
TW200815394A (en) 2008-04-01
CA2663598A1 (en) 2008-02-28
US20090137545A1 (en) 2009-05-28
WO2008022945A1 (de) 2008-02-28
CL2007002407A1 (es) 2009-03-27
AU2007287652A1 (en) 2008-02-28
SG169338A1 (en) 2011-03-30
ZA200810782B (en) 2009-11-25
KR20090047535A (ko) 2009-05-12
JP2010501514A (ja) 2010-01-21
NO20091025L (no) 2009-03-09
JP2012149086A (ja) 2012-08-09
EP2284166B1 (de) 2013-10-16
EA200900279A1 (ru) 2009-10-30
JP5529202B2 (ja) 2014-06-25
DE102006039003A1 (de) 2008-02-21
EP2061779A1 (de) 2009-05-27
SG169339A1 (en) 2011-03-30
US8252785B2 (en) 2012-08-28
IL197021A0 (en) 2009-11-18
NO20090079L (no) 2009-02-16
EP2061779B1 (de) 2013-11-06
EP2284166A1 (de) 2011-02-16
SG169337A1 (en) 2011-03-30
CN101516867A (zh) 2009-08-26
AR062426A1 (es) 2008-11-05
JP5650781B2 (ja) 2015-01-07

Similar Documents

Publication Publication Date Title
CO6160230A2 (es) Arilsulfonamidas con efecto analgesico
AR125414A2 (es) INHIBIDORES DE INTEGRINA avb6
PE20091381A1 (es) Inhibidores del virus de la hepatitis c
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CL2017000992A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasa
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
AR101692A1 (es) Compuestos y métodos para inhibir histonas demetilasas
EA200801160A1 (ru) Алкоксиалкилзамещённые спироциклические тетрамовые и тетроновые кислоты
EA201792046A1 (ru) Модуляторы рецептора андрогенов и их применение
AR063015A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer
ECSP099091A (es) Profarmaco de compuesto de cinamida
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
EA201100037A1 (ru) Органические соединения
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
AR055620A1 (es) Derivados de cicloalcano-carboxamidas
AR065322A1 (es) 2-aminooxazolinas comoligandos de taar1
CR10420A (es) Derivados biciclicos como inhibibidores de cetp
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
ES2436020T3 (es) Derivados de sulfonamida sustituidos
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
EA201000884A1 (ru) Производные 1,2-дизамещенного 4-бензиламинопирролидина в качестве ингибиторов белка-переносчика холестерилового эфира, используемые для лечения заболеваний, таких как гиперлипидемия или артериосклероз
CY1110190T1 (el) Παραγωγα πιπεραζινυλιου χρησιμα στην αγωγη των νοσων στις οποιες μεσολαβει ο υποδοχεας gpr38
AR078549A1 (es) Antagonistas de la via de wnt y composiciones farmaceuticas que los contienen
BR112015031432A2 (pt) compostos de carbazol carboxamida úteis como inibidores de cinase
AR042067A1 (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes